Experimental cocktail targets deadly brain cancer in early trial
NCT ID NCT03426891
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This early-phase study tested the safety of combining two drugs (pembrolizumab and vorinostat) with standard chemotherapy and radiation in 21 people with newly diagnosed glioblastoma, an aggressive brain cancer. The goal was to find the highest safe dose of vorinostat in this combination. While the drugs are approved for other cancers, they are not yet approved for glioblastoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.